Starpharma Holdings
Starpharma Holdings is an Australian biotechnology company focused on developing dendrimer technology for pharmaceutical and life science applications. Their proprietary dendrimer platform is used to improve drug delivery, enhance drug efficacy, and create new pharmaceutical products. The company's market position is built on its innovative technology and partnerships with pharmaceutical companies.
Short position
Starpharma Holdings (ASX:SPL) has 0.03% of its shares on issue reported as short positions as of 5 Oct 2026, or about 150,000 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.08 percentage points. Its highest recorded short interest was 5.92% in September 2013. SPL is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Starpharma Holdings (SPL) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $12.1Mvs $4.9M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$7.5Mvs −$10.0M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.017vs −$0.023 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +145.3%FY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 93.8%
- Operating margin
- −74.6%
- Net margin
- −62.0%
- FCF margin
- −29.0%
- ROE
- −45.6%
- ROA
- −33.6%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $10.7M
- Net debt / EBITDA
- n/a
- Current ratio
- 3.4×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $365.1M
- P/E
- n/a
- P/B
- 26.5×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $12.1M | $4.9M | $8.3M | $2.9M |
| Gross profit | $11.3M | $3.7M | $7.7M | $1.8M |
| Operating income | −$9.0M | −$12.0M | −$10.7M | −$18.2M |
| EBITDA | −$8.1M | −$10.9M | −$9.6M | −$17.0M |
| EBIT | −$9.0M | −$12.0M | −$10.7M | −$18.2M |
| Pretax income | −$7.5M | −$10.0M | −$8.2M | −$15.6M |
| Tax | $0 | $0 | $0 | $0 |
| NPAT | −$7.5M | −$10.0M | −$8.2M | −$15.6M |
| Net interest income | $616.0K | $938.0K | $1.5M | $1.3M |
| EPS basic | −$0.017 | −$0.023 | −$0.019 | −$0.039 |
| EPS diluted | −$0.017 | −$0.023 | −$0.019 | −$0.039 |
| Shares | 432.1M | 429.3M | 423.3M | 421.4M |
Financial reports
The company's own filings, newest first
- Preliminary Final ReportAnnual Results26 Aug 2026via asx_announcements
- 2026 Annual ReportAnnual Report26 Aug 2026via asx_announcements
- FY26 Key Financial Results and Annual ReportAnnual Report26 Aug 2026via asx_announcements
- Quarterly Activities Report and Appendix 4CQuarterly Report15 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results18 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Oct 2025via asx_announcements
- 2025 Appendix 4E Preliminary Financial ReportAnnual Results26 Aug 2025via asx_announcements
- FY25 Key Financial Results and Annual ReportAnnual Report26 Aug 2025via asx_announcements
Showing 10 of 21 reports